An Offer We Cannot Refuse: Cell-Free DNA as a Novel Biomarker of Myocardial Infarction
- 1 June 2018
- journal article
- editorial
- Published by Elsevier BV in The American Journal of the Medical Sciences
- Vol. 356 (2), 88-89
- https://doi.org/10.1016/j.amjms.2018.05.009
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (R00DK105160)
- Biomedical Laboratory Research and Development, VA Office of Research and Development (IK2BX003922)
This publication has 8 references indexed in Scilit:
- Correlations of Circulating Cell-Free DNA With Clinical Manifestations in Acute Myocardial InfarctionThe American Journal of the Medical Sciences, 2018
- Immune activation by nucleic acids: A role in pregnancy complicationsScandinavian Journal of Immunology, 2018
- The value of cell‐free DNA for molecular pathologyThe Journal of Pathology, 2018
- Cell-free DNA from human plasma and serum differs in content of telomeric sequences and its ability to promote immune responseScientific Reports, 2017
- Mutation analysis of circulating plasma DNA to determine response to EGFR tyrosine kinase inhibitor therapy of lung adenocarcinoma patientsScientific Reports, 2016
- A multifactorial relationship exists between total circulating cell‐free DNA levels and maternal BMIPrenatal Diagnosis, 2012
- Circulating mutant DNA to assess tumor dynamicsNature Medicine, 2008
- Body Fluid Proteomics for Biomarker Discovery: Lessons from the Past Hold the Key to Success in the FutureJournal of Proteome Research, 2007